Where does traction therapy fit in Peyronie’s care? Guidelines, conservative treatment, post-surgical rehab — and clear, honest boundaries.
If you’ve been told you have Peyronie’s disease — or you suspect you might — you’ve probably already discovered how confusing the treatment landscape is. Pills with thin evidence. Injections into the plaque. Surgery that trades curvature for length. And somewhere in the middle, mentioned almost in passing: traction therapy.
This article maps exactly where traction sits in Peyronie’s care, based on published guidelines and peer-reviewed studies — including where the evidence is thin, where traction doesn’t belong, and when you should be talking to a urologist instead of reading articles like this one.
Nothing here is a recommendation for any product. Traction devices don’t treat disease on their own, and no device replaces a diagnosis.
Peyronie’s disease is a connective-tissue disorder of the tunica albuginea — the fibrous sheath surrounding the erectile tissue. For reasons still not fully understood (most likely repeated micro-trauma during intercourse), a fibrous plaque forms. That plaque doesn’t stretch like the surrounding tissue, so the penis bends toward it during erection. Pain during erections is common early on; erectile dysfunction often follows, partly from the deformity itself and partly from the anxiety it causes.
Urologists think about the condition in two phases, and the distinction matters for every treatment decision:
Any honest discussion of traction therapy has to start here, because when you use it matters as much as whether you use it.
Peyronie’s care is usually described as a ladder of escalating invasiveness. Simplified, it looks like this:
Traction’s rung is the conservative, non-invasive one. It doesn’t dissolve plaque the way an enzyme injection aims to, and it doesn’t straighten the way surgery does. Its proposed mechanism is slower and more mechanical: sustained tension remodels fibrotic tissue over time — the same mechanotransduction principle behind orthodontic braces and surgical tissue expansion.
Understanding this placement is the whole point. Traction is not an alternative to the ladder. It’s one rung on it.
This is where honesty requires some nuance, because the guidelines don’t all speak with one voice.
The European Association of Urology (EAU) Guidelines on Penile Curvature (Hatzimouratidis et al.) include a direct recommendation: “Use penile traction devices and vacuum devices to reduce penile deformity and increase penile length.” That sounds strong until you look at the grading: level of evidence 2b, grade C recommendation. In guideline language, Grade C is a weak recommendation — it means “we think this is reasonable, but the evidence behind it is modest.” That’s not a dismissal; it’s a calibration. The EAU put traction on the map, with an asterisk.
The American Urological Association (AUA) guideline (Nehra et al., 2015) lists penile traction under “mechanical therapies” among the evaluated options, again without strong endorsement.
A 2023 Cochrane review of non-surgical Peyronie’s therapies put it bluntly: the AUA, Canadian, European, and international societies all “with different qualifiers, see a role for penile traction therapy” — but the review’s main finding was the high degree of uncertainty around patient-important outcomes. And a 2021 European Society for Sexual Medicine position statement concluded there wasn’t enough evidence to warrant a formal treatment recommendation at all.
So the fair summary is this: major guidelines include traction therapy as a conservative option, but the recommendations are weak, the societies don’t fully agree, and the evidence base is the limiting factor — not the idea itself. Anyone who tells you “guidelines prove it works” is overselling. Anyone who tells you “guidelines reject it” is misreading.
The literature on traction for Peyronie’s is small but not empty. Here are the studies that matter, with their limitations attached — because the limitations are part of the story.
Levine et al., 2008 — the pilot. Ten men with Peyronie’s used a traction device in a pilot study published in the Journal of Sexual Medicine. Average curvature decreased by about a third, and stretched length increased by 0.5 to 2.5 cm. No adverse events were reported. Ten patients is a conversation starter, not a conclusion — but it was the study that got urologists to take traction seriously.
Ziegelmann et al., 2019 — the randomized trial. This is the strongest study in the field. At Mayo Clinic, 110 men with Peyronie’s (average curvature about 59 degrees) were randomized 3:1 to a traction device used 30–90 minutes per day or to no therapy, for three months (Journal of Urology, PMID 30916626). Compared with controls, the traction group gained 1.5 cm in length versus 0 cm (p<0.001), reduced curvature by 11.7 degrees versus a 1.3-degree worsening in controls (p<0.01), and men with erectile dysfunction saw meaningful improvement in erectile function scores. Seventy-seven percent saw curvature improve; 94% gained length (average 1.6 cm). Side effects were mild and transient. A follow-up phase (Joseph et al., Journal of Sexual Medicine, 2020) reported continued gains at 6 and 9 months. The authors’ own stated limitations: the sample size was too small for comparisons between subgroups, and there was no long-duration treatment arm.
A second randomized trial using a different device (Penimaster PRO) also reported improvements in curvature, stretched length, and questionnaire scores, according to a 2025 narrative review in the urology literature. Two independent randomized trials pointing the same direction is meaningful — even if two is still a small number.
Haney et al., 2018 — the meta-analysis. Pooling four studies (348 men), researchers found that traction used as an add-on after injections or surgery was associated with 1.02 cm greater stretched length than no traction (p=0.009, Urology). Note the context carefully: this is traction supporting a primary treatment and preserving length afterward — not traction as a stand-alone cure. The reviewers themselves flagged that most included studies weren’t randomized and that a one-centimeter average gain, while statistically significant, is of debated clinical significance.
Side effects, across the literature, are consistently described as mild and self-limiting: temporary discomfort or pain, redness, small bruises, itching. That’s reassuring but not a blank check — these were studied populations using devices as directed, often under clinical supervision.
Putting the guidelines and studies together, traction therapy’s honest place in Peyronie’s care looks like this:
And just as important: traction’s value in the research is tied to consistent, supervised use over months. The trials that showed results used defined protocols with clinical follow-up. A device bought online and used sporadically is not the thing that was studied.
Traction therapy is not appropriate for every penile curvature, and self-treating the wrong condition wastes time at best. See a urologist — before doing anything else — if any of the following apply:
One more boundary worth stating plainly: no traction device treats Peyronie’s disease in the sense of curing it. The research describes improvements in measured outcomes — degrees of curvature, centimeters of length — in studied populations. That’s genuinely interesting. It is not the same as a cure, and any marketing that blurs that line is selling you something the science doesn’t say.
A few things the papers imply but don’t emphasize:
Compliance is the hard part. The trials showing results required months of daily use. Older devices in these studies demanded 3–8 hours a day — a regimen most men can’t sustain, which is exactly why dropout and poor compliance plague this literature. Shorter daily protocols (like the 30–90 minutes in the RestoreX trial) exist, but “shorter” still means every day, for months.
Mild side effects are common; serious ones are rare in the literature. Temporary redness, soreness, or small bruises are frequently reported and resolve quickly. Anything persistent — numbness, significant pain, skin breakdown — means stop and get medical advice.
Supervision matters. The best results in the literature came from men enrolled in trials with clinical follow-up. If you’re considering traction for Peyronie’s, the studied version of this story involves a urologist who knows you’re doing it.
Penile traction therapy has earned a legitimate, if modest, place in Peyronie’s care: included in major guidelines with weak recommendations, supported by a small but real body of peer-reviewed research, most convincing as a conservative option or as an add-on that protects length around other treatments. The evidence is not strong enough to promise any individual man a result — and anyone who promises you one isn’t reading the same literature.
If there’s one thing to take from this article, it’s the order of operations: diagnosis first, urologist second, decisions about devices a distant third. The science is interesting enough to deserve your attention. Your health deserves more than interesting — it deserves a clinician.
We publish articles like this one because this field desperately needs them. The internet is full of confident claims about Peyronie’s treatments — most of them selling something, few of them citing anything. We believe the antidote is honest literature: what the studies actually say, where the evidence thins out, and when the right answer is “see a doctor.” If we can help readers develop better judgment about the information they’re drowning in, that’s worth more to us than any single sale. Earning trust slowly is the whole business model.
A final, personal note: I know this is a difficult topic to research. There’s embarrassment in looking it up, frustration in the conflicting advice, and no shortage of people willing to sell you certainty. I can’t examine you, and this article can’t tell you what to do — it’s information, not medical advice. What I can do is promise that everything above is what the published literature actually says, limitations included. If something here resonates with your situation, please take it to a urologist. That’s not a formality; it’s the most important sentence in this article.